文献速递慢性肾脏病水电解质与酸碱血液净化与透析

高铁蛋白血症、铁缺乏与澳大利亚原住民CKD贫血管理挑战的叙述性综述

Narrative Review of Hyperferritinemia, Iron Deficiency, and the Challenges of Managing Anemia in Aboriginal and Torres Strait Islander Australians With CKD.
PubMed 文献 · Kidney Int Rep · 2020-11-10

澳大利亚原住民慢性肾脏病(CKD)患病率极高,偏远地区肾脏替代治疗(RRT)患病率可达全国30倍。贫血常见,铁缺乏是主因且影响促红细胞生成素(ESA)疗效。常规依赖血清铁蛋白和转铁蛋白饱和度(TSAT)识别铁缺乏,但铁蛋白受炎症影响常显著升高,超出多数指南范围。本综述探讨原住民CKD贫血管理挑战及未来研究方向。

要点

  • 原住民CKD贫血常见,铁缺乏是主因且影响ESA反应。
  • 血清铁蛋白受炎症影响,原住民RRT患者常显著升高。
  • 高铁蛋白伴铁缺乏者的贫血治疗疗效与安全性需未来研究。

核心结论

  • 原住民CKD贫血管理面临挑战,高血清铁蛋白与铁缺乏并存时治疗证据不足,需未来研究。

研究设计与样本

  • 叙述性综述,检索已发表数据,探讨原住民CKD贫血管理挑战。

主要发现

  • 偏远地区原住民RRT患病率高达全国30倍。
  • 铁缺乏是CKD贫血主因及ESA反应不佳的关键原因。
  • 原住民RRT患者血清铁蛋白常显著升高,超出多数指南范围。

关键数值与推荐

  • 常规用血清铁蛋白和TSAT作为铁状态替代标志物。
  • 血清铁蛋白是急性期反应物,炎症时可升高。

临床怎么用

  • 原住民CKD贫血管理需重视铁缺乏识别与纠正,但高铁蛋白时需谨慎解读。

局限性

  • 为叙述性综述,未报告系统检索策略或定量合并。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aboriginal and Torres Strait Islander Australians (Indigenous Australians) suffer some of the highest rates of chronic kidney disease (CKD) in the world. Among Indigenous Australians in remote areas of the Northern Territory, prevalence rates for renal replacement therapy (RRT) are up to 30 times higher than national prevalence. Anemia among patients with CKD is a common complication. Iron deficiency is one of the major causes. Iron deficiency is also one of the key causes of poor response to the mainstay of anemia therapy with erythropoiesis-stimulating agents (ESAs). Therefore, the effective management of anemia in people with CKD is largely dependent on effective identification and correction of iron deficiency. The current identification of iron deficiency in routine clinical practice is dependent on 2 surrogate markers of iron status: serum ferritin concentration and transferrin saturation (TSAT). However, questions exist regarding the use of serum ferritin concentration in people with CKD because it is an acute-phase reactant that can be raised in the context of acute and chronic inflammation. Serum ferritin concentration among Indigenous Australians receiving RRT is often markedly elevated and falls outside reference ranges within most national and international guidelines for iron therapy for people with CKD. This review explores published data on the challenges of managing anemia in Indigenous people with CKD and the need for future research on the efficacy and safety of treatment of anemia of CKD in patients with high ferritin and evidence iron deficiency.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Majoni SW, Lawton PD, Rathnayake G, et al. Narrative Review of Hyperferritinemia, Iron Deficiency, and the Challenges of Managing Anemia in Aboriginal and Torres Strait Islander Australians With CKD. Kidney Int Rep. 2020. PMID: 33615076. doi:10.1016/j.ekir.2020.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。